Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Customized Antibiotic Duration (CDA) Strategy in Acute Exacerbations of COPD
NCT07708337Not yet recruiting
- Sponsor
- Capital Development Authority
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Capital Development Authority. Primary endpoint: Clinical Success at Day 30. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07708337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708337.